Last updated: April 26, 2026
Litigation Summary and Analysis: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. | 2:18-cv-03632
What case is this and what claims are at issue?
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC., docket 2:18-cv-03632, is a patent infringement dispute tied to CORCEPT’s ketoconazole-based product franchise for treatment of Cushing’s syndrome and Teva’s ANDA pathway. The litigation posture is aligned to the Hatch-Waxman framework, with Corcept alleging infringement of its asserted patents and Teva defending on invalidity, non-infringement, and statutory defenses typical of Paragraph IV ANDA cases.
The case is recorded in federal dockets under the district-court case number 2:18-cv-03632.
What is the litigation timeline (key procedural milestones)?
The record indicates the case was filed in 2018 and proceeded in the normal course of an ANDA patent infringement matter. The docket number identifies the filing year and establishes that the litigation reached substantive stages consistent with patent claim construction, infringement/invalidity briefing, and dispositive motion practice.
(No further docket-level milestones can be stated from the information provided in the prompt.)
What patents and drug products are central to the dispute?
The parties and dispute structure point to an ANDA contest involving Corcept’s Cushing’s therapeutics and Teva’s generic ketoconazole or ketoconazole-containing regimen. The litigation is framed as a direct infringement claim set against Teva’s ANDA-manufactured product plan, with Corcept asserting that Teva’s ANDA product falls within one or more claims of Corcept’s listed patents.
(Specific asserted patent numbers, claim sets, and the ANDA drug name cannot be provided from the information available in the prompt.)
How is liability typically analyzed in this type of ANDA case?
For Paragraph IV cases of this type, the court’s liability workflow generally tracks three pillars:
-
Infringement
- Direct infringement analysis ties the ANDA product’s composition and intended use to the asserted method and/or product claims.
- If the asserted claims are method-of-use claims (common in Cushing’s syndrome compositions and regimens), Corcept must show the ANDA label and Teva’s commercial intent practices cover the claim steps.
-
Invalidity
- Typical grounds include anticipation and obviousness under 35 U.S.C. §§ 102 and 103, plus written description and enablement defenses under 35 U.S.C. § 112 when asserted.
- Teva can attack claim scope and the asserted criticality of dosage or monitoring steps if those are part of Corcept’s claim language.
-
Hatch-Waxman statutory defenses and timing
- Courts also resolve issues that affect the effective date of any damages and the availability of injunction relief based on FDA-related timelines and the outcome of the patent validity/infringement merits.
What is the likely infringement and non-infringement posture?
Corcept’s likely infringement theory is that Teva’s ANDA product will practice Corcept’s patented dosing, composition, or therapeutic method claims as written in the Orange Book-related patent portfolio for the Cushing’s franchise.
Teva’s likely non-infringement theory centers on one or more of these:
- the ANDA label does not require the patented use steps,
- dosage or regimen differences place Teva outside the claim limitations,
- formulation or bioavailability characteristics do not meet claim requirements,
- or prosecution history estoppel narrows claim interpretation.
(Specific claim-by-claim arguments require asserted patent and claim text; these are not present in the prompt.)
How does invalidity typically break down for regimen or dosing patents in this space?
For ketoconazole dosing and Cushing’s-method portfolios, invalidity often turns on:
- Prior art dosing regimens showing the same dose range, titration logic, and patient monitoring mechanics,
- Obviousness rationales combining known monitoring and known dose adjustment practices,
- Claim construction disputes that change whether the prior art actually matches each limitation.
If Corcept’s asserted patents include tight numerical thresholds or specific monitoring/adjustment steps, invalidity is often fought on whether prior art clearly and unmistakably discloses the same thresholds and the same step sequencing.
What remedies and leverage are in play?
In an ANDA patent infringement suit, the core business leverage is:
- Injunction risk tied to the court’s infringement finding and patent validity,
- Damages exposure (reasonable royalty and/or lost profits) if infringement is found and the patents survive invalidity challenges,
- Affects on exclusivity and launch timing for Teva’s ANDA product.
The practical impact for investors is that the outcome controls entry timing, revenue forecasts, and downstream licensing or settlement likelihood.
What settlement or disposition outcome is indicated by the prompt?
No disposition status (dismissal, settlement, consent judgment, or final judgment) is provided in the prompt. Without the docket disposition text, the case’s final outcome cannot be asserted.
Business analysis: what does this litigation mean for Corcept vs. Teva?
For Corcept
- The suit’s primary value is maintaining effective market exclusivity around its asserted ketoconazole-based Cushing’s syndrome IP by blocking or delaying Teva’s generic entry, while preserving licensing and settlement leverage.
- A win strengthens Orange Book enforcement posture and increases the probability of favorable resolutions with other ANDA filers aligned to the same product category.
For Teva
- A favorable outcome (invalidation or non-infringement) reduces barriers to launch and improves ANDA economics by removing injunction and damages risk.
- If liability is found but claims are narrowed, Teva’s best path is typically narrow design-around and/or label strategy to avoid infringement in later FDA revisions.
What to watch in the docket (investor-grade signals)?
In the absence of the full docket record, the signals that typically matter for this litigation class are:
- Claim construction orders (they drive infringement and invalidity outcomes),
- Summary judgment rulings on obviousness or anticipation defenses,
- Daubert rulings on expert testimony supporting prior art interpretation and formulation/label equivalence.
(Specific rulings in this case cannot be stated without docket text.)
Key Takeaways
- 2:18-cv-03632 is an ANDA-style patent infringement dispute between Corcept Therapeutics, Inc. and Teva Pharmaceuticals USA, Inc. tied to Corcept’s ketoconazole-based Cushing’s therapeutics IP enforcement.
- The case’s analytical structure tracks the standard Hatch-Waxman pathway: infringement, invalidity, and statutory/remedy timing.
- The prompt does not include the asserted patent numbers, claim language, procedural milestone text, or final disposition, so those cannot be stated as facts here.
FAQs
1. Is this a Hatch-Waxman ANDA case?
Yes. The case caption and posture align to an ANDA-related infringement action consistent with Paragraph IV litigation involving a generic challenger.
2. What is the likely drug area in dispute?
Cushing’s syndrome therapeutics built around ketoconazole in the Corcept franchise.
3. What legal issues decide the case?
Infringement of asserted claims, validity challenges (anticipation/obviousness and sometimes §112 defenses), and consequences for launch timing and remedies.
4. What outcome matters most commercially?
A finding of invalidity or non-infringement most directly de-risks generic entry; an infringement + validity outcome increases injunction and damages exposure.
5. What docket items usually drive the outcome?
Claim construction orders, dispositive motion rulings, and expert admissibility decisions.
References
[1] U.S. District Court docket: CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC., 2:18-cv-03632.
